Strong Early Promise For Takeda 'Off The Shelf' CAR-NK Therapy
Successful, Safe And Simple Alternative?
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
You may also be interested in...
While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.
Giving cell therapies as outpatient rather than inpatient treatments could be a way around the need for bundled payments, but it’s not universally applicable.
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.